Quantcast

Latest Cardiac surgery Stories

2014-09-23 08:30:52

PubMed-indexed case report---with matching video---by surgeons at Texas Children's Hospital and Cincinnati Children's Hospital concludes that the SynCardia Total Artificial Heart can be modified for use in patients whose hearts have congenital abnormalities. TUCSON, Ariz., Sept. 23, 2014 /PRNewswire/ -- A case report and matching animated video demonstrate the successful implantation of a SynCardia temporary Total Artificial Heart into a patient with congenital heart disease where his major...

2014-09-18 23:00:49

Heart Transplant program becomes one of only two programs in South Florida. Hollywood, Florida (PRWEB) September 18, 2014 Memorial Cardiac and Vascular Institute at Memorial Regional Hospital made history this week by performing the first ever, adult heart transplant in Broward County. The hospital received UNOS (United Network for Organ Sharing) approval to launch the adult heart transplant program earlier this year, becoming one of only two programs in South Florida. The skilled...

2014-09-17 08:29:17

Third Multi-Center Study Shows Compelling Results Consistent with Previous Trials; Data Presented at TCT KIRKLAND, Wash., Sept. 17, 2014 /PRNewswire/ -- Cardiac Dimensions(®), Inc. today announced that new long-term outcomes data from the TITAN II clinical trial of its enhanced CARILLON Mitral Contour System showed significant and sustained improvements in mitral regurgitation, functional improvement, quality of life and reverse cardiac remodeling. The long-term safety and efficacy data,...

2014-09-16 12:24:58

Peer-reviewed case report says implantation of the SynCardia Total Artificial Heart restores "normal biventricular circulation" to a congenital patient with only one functioning ventricle. The male patient was bridged to a donor heart 61 days later. TUCSON, Ariz., Sept. 16, 2014 /PRNewswire/ -- Surgeons at The Children's Hospital of Philadelphia describe in a case report the first successful use of a SynCardia temporary Total Artificial Heart (TAH-t) in a 13- year-old boy with failing Fontan...

2014-09-15 16:28:52

No Cases of Moderate or Severe Paravalvular Aortic Regurgitation at One Year MARLBOROUGH, Mass., Sept. 15, 2014 /PRNewswire/ -- New data from the Boston Scientific (NYSE: BSX) clinical trial program of the Lotus(TM) Valve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year,...

2014-09-15 12:27:22

Tiara(TM) Transcatheter Mitral Valve program featured in multiple scientific presentations NASDAQ: NVCNTSX: NVC WASHINGTON, DC, Sept. 15, 2014 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) announced today that its Reducer(TM) technology was featured in a "live case" broadcast on Sunday, September 14, 2014 at the 26th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. A Clinical update on the company's Tiara(TM)...

2014-09-13 12:20:33

Transcatheter Valve Durability Sustained Through Five Years WASHINGTON, Sept. 13, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced the presentation of five-year clinical outcomes for inoperable patients treated in The PARTNER Trial, the world's only prospective randomized trial for transcatheter aortic valve replacement (TAVR) in patients deemed too sick for open-heart...

2014-09-10 08:29:45

Harpoon Medical Has Received More than $3M of its Series A Financing to Fund the Initial Clinical Evaluation of the Company's Minimally Invasive Mitral Valve Repair Device STEVENSVILLE, Md., Sept. 10, 2014 /PRNewswire/ -- Harpoon Medical, Inc., a medical device company focused on the development and commercialization of a minimally invasive, beating heart mitral valve repair technology, announced today that the company has successfully raised $3.2M of new capital and expects to...

2014-09-09 12:29:07

STASIS Clinical Study Begins in Europe NEWTOWN, Pa., Sept. 9, 2014 /PRNewswire/ -- Micro Interventional Devices, Inc. (MID) reports the first successful clinical case using its Permaseal Cardiac Access and Closure technology. This new technology simplifies minimally invasive aortic valve replacement procedures. The patient is the first to be enrolled in the Secure Transapical Access and Closure Study (STASIS) being conducted in Europe. The first STASIS case was performed by Dr....

2014-09-09 08:31:27

MONMOUTH JUNCTION, N.J., Sept. 9, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a blood purification company using its CytoSorb® extracorporeal cytokine adsorber to prevent or treat organ failure in life-threatening conditions, announced its U.S. Cardiac Surgery Advisory Board (CSAB) that includes leaders in cardiothoracic surgery, surgical critical care, extracorporeal therapy, and inflammation. The Board will oversee the use of CytoSorb® in cardiac surgery trials...


Latest Cardiac surgery Reference Libraries

0_886104d1c1c698f3a531e056704457d5
2010-10-14 16:46:25

The artificial heart, a mechanical heart replacement, is typically used in order to bridge the time to heart transplant or to replace the heart in case a transplant is impossible. Often ventricular assist devices are confused with mechanical hearts because the assist the heart through pumps. They are also different from a cardiopulmonary bypass machine which is an external device used to provide the function of the heart and lungs. CPBs are usually only used for a few hours at a time,...

More Articles (1 articles) »
Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.